Risk factors for primary prevention of cardiovascular disease and risk reduction by lipid control: the OMEGA study risk factor sub-analysis

References

• Fujita T, Teramoto T. Drug therapy for hypertension and hyperlipidemia – current status and challenges; Japan Guideline Assessment Panel (J-GAP). Prog Med 2006;26:2297–306. (in Japanese)
   Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32:3–107
   PubMed Web of Science ®Google Scholar
• Teramoto T, Kawamori R, Miyazaki S, et al. Relationship between achieved blood pressure, dietary habits and cardiovascular disease in hypertensive patients treated with olmesartan: the OMEGA Study. Hypertens Res 2012;35:1136–44
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155–63
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J Am Med Assoc 1998;279:1615–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149–58
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685–96
   PubMed Web of Science ®Google Scholar
• Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2012. Japan: Japan Atherosclerosis Society;2012
   Google Scholar
• Teramoto T, Fujita T, Kawamori R, et al. OMEGA Study: design, baseline data, metabolic syndrome prevalence in a large-scale observational study of hypertensive patients: the Olmesartan Mega Study to Determine the Relationship between Cardiovascular Endpoints and Blood Pressure Goal Achievement Study. Hypertens Res 2008;31:2011–17
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kita Y, Nakamura Y, et al. Incidence of acute myocardial infarction in Takashima, Shiga, Japan. Circ J 2005;69:404–8
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837–47
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434–44
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Wheatley K, et al. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994;309:901–11
   PubMed Web of Science ®Google Scholar
• Kiyohara Y, Ueda K, Fujishima M. Smoking and cardiovascular disease in the general population in Japan. J Hypertens 1990;8:S9–S15
   Web of Science ®Google Scholar
• Matsuzaki M, Kita T, Mabuchi H, et al. Japan Lipid Intervention Trial. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002;66:1087–95
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. J Am Med Assoc 2004;291:2204–11
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Ueshima H, Kadota A, et al. Alcohol intake and 19-year mortality in diabetic men: NIPPON DATA 80. Alcohol 2009;43:635–41
   PubMed Web of Science ®Google Scholar
• Arakawa K, Matsushita Y, Matsuo H, et al. Examination of the efficiency of salt taste preference questionnaire in hypertensive patients – results from post marketing surveillance of Olmetec® tablets and Calblock® tablets. J Clin Ther Med 2009;25:723–34. (in Japanese)
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87
   PubMed Web of Science ®Google Scholar
• Intersalt Cooperative Research Group. Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Br Med J 1988;297:319–28
   PubMed Web of Science ®Google Scholar
• Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3–10
   PubMed Web of Science ®Google Scholar
• Kawano Y, Ando K, Matsuura H, et al. Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension. Report of the Working Group for Dietary Salt Reduction of the Japanese Society of Hypertension: (1) Rationale for salt restriction and salt-restriction target level for the management of hypertension. Hypertens Res 2007;30:879–86
   PubMed Web of Science ®Google Scholar
• He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002;16:761–70
   PubMed Web of Science ®Google Scholar
• Cook NR, Cutler JA, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). Br Med J 2007;334:885–8
   PubMed Web of Science ®Google Scholar
• Nagata C, Takatsuka N, Shimizu N, Shimizu H. Sodium intake and risk of death from stroke in Japanese men and women. Stroke 2004;35:1543–7
   PubMed Web of Science ®Google Scholar
• Teramoto T, Kawamori R, Miyazaki S, Teramukai S;OMEGA Study Group. Sodium intake in men and potassium intake in women determine the prevalence of metabolic syndrome in Japanese hypertensive patients: OMEGA Study. Hypertens Res 2011;34:957–62
   PubMed Web of Science ®Google Scholar
• Teramoto T, Nakaya N, Yokoyama S, et al. Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese. J Atheroscler Thromb 2010;17:879–87
   PubMed Web of Science ®Google Scholar